Safety of Oral Propranolol for Infantile Hemangioma

Pediatrics
Catherine DroitcourtAlain Dupuy

Abstract

The safety of oral propranolol for infantile hemangioma has not yet been studied at population level since the pediatric use marketing authorization was obtained in Europe. A survey of a nationwide, claim-based observational cohort of children <3 years old, with at least 1 delivery of oral propranolol between July 2014 and June 2016, was performed by using the database of the French National Health Insurance system. Standardized morbidity ratios (SMRs) were calculated by using, from the same database, a representative random sample of nonexposed subjects. The main outcomes were hospitalizations for cardiovascular (conduction disorders, bradycardia, and hypotension), respiratory (bronchial hyperactivity and bronchospasm), or metabolic events (hypoglycemia and hyperkalaemia), identified through the hospitalization diagnostic codes of the International Classification of Diseases, 10th Revision. The main analysis was conducted separately on "healthy" children (N = 1484), that is, free from of any prespecified underlying disease and on children with 1 of these underlying diseases (N = 269). In all, 1753 patients <3 years of age had at least 2 deliveries of oral propranolol. In the healthy population, we observed 2 cardiovascular eve...Continue Reading

References

Jan 1, 1996·The Journal of Pediatrics·N Sadan, B Wolach
Apr 17, 1998·The Journal of Pediatrics·C F BarlowR A Ezekowitz
Jun 14, 2008·The New England Journal of Medicine·Christine Léauté-LabrèzeAlain Taïeb
Aug 27, 2009·Pediatrics·Véronique SansChristine Léauté-Labrèze
Oct 28, 2009·Pediatrics·Denise MetryUNKNOWN PHACE Syndrome Research Conference
Feb 19, 2015·The New England Journal of Medicine·Christine Léauté-LabrèzeJean-Jacques Voisard
Jan 28, 2016·JAMA : the Journal of the American Medical Association·Sorilla PreyKhaled Ezzedine
Jun 29, 2016·Fundamental & Clinical Pharmacology·Aurore PalmaroMaryse Lapeyre-Mestre
Oct 1, 2016·Pediatrics·Christine Léaute-LabrèzeJean-Jacques Voisard
Jan 17, 2017·Lancet·Christine Léauté-LabrèzePeter H Hoeger
May 26, 2017·Pharmacoepidemiology and Drug Safety·Julien BezinNicholas Moore

❮ Previous
Next ❯

Citations

Jun 4, 2020·Pediatrics International : Official Journal of the Japan Pediatric Society·Kohei GotoToshiyuki Fukao
Jul 15, 2020·Expert Review of Clinical Pharmacology·Sabrina P KohSwee T Tan
May 19, 2019·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·Antonia Reimer, Hagen Ott
Oct 30, 2020·British Journal of Clinical Pharmacology·Floriane SocchiArthur Gavotto
Jul 16, 2021·International Journal of Cardiology·Samar R El KhoudaryBernhard Kühn
May 10, 2020·Current Pediatric Reviews·Alexander K C LeungKam L Hon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.